Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 349.34K | 60.00K | 15.37K | 27.15K | 211.48K | 0.00 |
Gross Profit | -316.83K | -1.57M | -824.86K | -922.60K | -48.00K | -196.23K |
EBITDA | -3.06M | -3.31M | -2.36M | -1.39M | -1.14M | -869.05K |
Net Income | -5.11M | -4.44M | -3.40M | -2.08M | -1.49M | -1.13M |
Balance Sheet | ||||||
Total Assets | 10.99M | 12.43M | 14.67M | 14.12M | 14.58M | 11.30M |
Cash, Cash Equivalents and Short-Term Investments | 516.27K | 277.80K | 680.58K | 311.83K | 2.05M | 2.01M |
Total Debt | 4.30M | 4.81M | 6.37M | 5.56M | 5.36M | 1.04M |
Total Liabilities | 4.91M | 5.59M | 7.28M | 6.47M | 5.97M | 1.54M |
Stockholders Equity | 6.07M | 6.84M | 7.38M | 7.65M | 8.61M | 9.76M |
Cash Flow | ||||||
Free Cash Flow | -3.12M | -3.87M | -3.23M | -2.61M | -2.96M | -3.02M |
Operating Cash Flow | -3.27M | -3.23M | -1.41M | 311.82K | 47.25K | 120.19K |
Investing Cash Flow | -274.88K | -711.05K | -1.98M | -3.08M | -3.00M | -3.14M |
Financing Cash Flow | 4.03M | 3.54M | 3.75M | 1.03M | 2.99M | 4.11M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
49 Neutral | AU$2.50B | 4.42 | -64.25% | 2.77% | 36.51% | 13.14% | |
46 Neutral | AU$2.68M | ― | -392.18% | ― | ― | 34.26% | |
46 Neutral | AU$11.11M | ― | -64.72% | ― | 139.19% | 33.33% | |
42 Neutral | AU$10.08M | ― | -180.09% | ― | ― | 28.57% | |
37 Underperform | AU$9.92M | ― | -80.47% | ― | -41.19% | 20.93% |
Memphasys Limited has submitted a CE Mark application for its Felix™ sperm separation device, marking a significant step in its global commercialization strategy. This milestone is expected to unlock commercial access in the EU and accelerate approvals in other regions, enhancing the company’s market positioning in the rapidly growing IVF sector. The Felix™ device offers a significant reduction in sperm preparation time, which is crucial for improving efficiency in fertility clinics. Memphasys is adopting a direct commercialization approach in markets with lower regulatory requirements, such as Japan, Canada, and New Zealand, to build early momentum and demonstrate the device’s value, while strategic distribution partnerships remain a long-term focus.
Memphasys Limited has appointed Marjan Mikel as a Non-Executive Director, bringing extensive experience in business development and commercialisation across the Medtech, diagnostics, healthcare services, and life sciences sectors. Mikel’s previous roles and familiarity with Memphasys’ strategic vision are expected to aid the company’s global expansion of its Felix™ system and accelerate the commercialisation of the RoXsta™ platform.
Memphasys Limited has announced a change in its external auditors, appointing BDO Audit Pty Ltd following the resignation of Pitcher Partners. This decision comes as part of a corporate review by the Board, aligning with the company’s strategic move towards the international commercialization of its Felix™ Device.
Memphasys Ltd has completed a placement of 212,583,334 ordinary shares at $0.006 per share without disclosure under Part 6D.2 of the Corporations Act. The company has ensured compliance with relevant provisions of the Corporations Act, indicating transparency and adherence to regulatory standards, which may bolster investor confidence.
Memphasys Ltd announced the application for quotation of 212,583,334 ordinary fully paid securities on the ASX, issued as part of a previously announced transaction. This move is expected to enhance the company’s market presence and provide additional capital for its operations, potentially impacting its industry positioning and offering new opportunities for stakeholders.
Memphasys Ltd has announced an update regarding the proposed issue of securities, with changes to the issue date and option expiry date now set for April 15, 2025, and April 15, 2027, respectively. This update reflects the company’s strategic financial maneuvers to leverage its ASX Listing Rule 7.1 capacity, potentially impacting its market positioning and providing stakeholders with revised timelines for investment opportunities.
Memphasys Limited has secured A$1.275 million through a strategic placement to advance the commercialisation of its Felix™ and RoXsta™ systems. The funds will support licensing, joint ventures, and distribution agreements, particularly following successful clinical trial results for the Felix™ System, which demonstrated superior performance to existing sperm preparation methods. The RoXsta™ System is gaining traction in veterinary applications, showing potential for livestock reproductive health and early mastitis detection in dairy cattle.
Memphasys Ltd has announced a proposed issue of 212,500,000 new securities, which will be fully paid ordinary shares. This move is part of a placement or other type of issue, with the proposed issue date set for April 11, 2025. This announcement could potentially impact the company’s market positioning by increasing its capital base, which may be used for further business development or operational expansion.